Role of olmesartan in combination therapy in blood pressure control and vascular function

References

• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentBlood Press20091830834720001654
   PubMed Web of Science ®Google Scholar
• ManciaGZanchettiAEuropean Society of Hypertension-European Society of CardiologyChoice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usageJ Hypertens20082616416818192825
   PubMed Web of Science ®Google Scholar
• ZanchettiAManciaGBlackHRFacts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertensionJ Hypertens20092767367919516168
   PubMed Web of Science ®Google Scholar
• IzzoJLJrPurkayasthaDHallDHilkertRJComparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertensionJ Hum Hypertens20102440340919890370
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med20083592417242819052124
   PubMed Web of Science ®Google Scholar
• BrunnerHRThe new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewJ Hum Hypertens200216Suppl 2S13S1611967728
   PubMedGoogle Scholar
• BrunnerHRLaeisPClinical efficacy of olmesartan medoxomilJ Hypertens Suppl200321S43S4612929907
   PubMedGoogle Scholar
• FerrarioCEffect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomilVasc Health Risk Manag2009530131419436655
   PubMedGoogle Scholar
• SchindlerCFerrarioCMOlmesartan for the treatment of arterial hypertensionFuture Cardiol2008435737219804316
   PubMedGoogle Scholar
• KoikeHSadaTMizunoMIn vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonistJ Hypertens Suppl200119S3S1411451212
   PubMedGoogle Scholar
• KoikeHNew pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonistAm J Cardiol20018733C36C
   PubMed Web of Science ®Google Scholar
• LaeisPPuchlerKKirchWThe pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interactionJ Hypertens Suppl200119S21S3211451211
   PubMedGoogle Scholar
• MizunoMSadaTIkedaMPharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonistEur J Pharmacol19952851811888566137
   PubMed Web of Science ®Google Scholar
• YoshidaKKohzukiMClinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonistCardiovasc Drug Rev20042228530815592575
   PubMedGoogle Scholar
• MurdochDHeelRCAmlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular diseaseDrugs1991414785051711448
   PubMed Web of Science ®Google Scholar
• RohatagiSLeeJShenoudaMPharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combinationJ Clin Pharmacol2008481309132218974285
   PubMed Web of Science ®Google Scholar
• FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation20041101103110715313950
   PubMed Web of Science ®Google Scholar
• LorenzenJMNeunhofferHDavidSKielsteinJTHallerHFliserDAngiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension – results from the EUTOPIA trialAtherosclerosis201020918418819801149
   PubMed Web of Science ®Google Scholar
• MiyazakiMTakaiSAnti-atherosclerotic efficacy of olmesartanJ Hum Hypertens200216Suppl 2S7S1211967727
   PubMedGoogle Scholar
• IchikawaSTakayamaYLong-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patientsHypertens Res20012464164611768722
   PubMed Web of Science ®Google Scholar
• SchindlerCBrosnihanKBFerrarioCMComparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjectsJ Clin Pharmacol20074711212017192509
   PubMed Web of Science ®Google Scholar
• CrackowerMASaraoROuditGYAngiotensin-converting enzyme 2 is an essential regulator of heart functionNature200241782282812075344
   PubMed Web of Science ®Google Scholar
• FerrarioCMJessupJChappellMCEffect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2Circulation20051112605261015897343
   PubMed Web of Science ®Google Scholar
• FerrarioCMTraskAJJessupJAAdvances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular functionAm J Physiol Heart Circ Physiol2005289H2281H229016055515
   PubMed Web of Science ®Google Scholar
• FerrarioCMNew physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolismHypertension20105544545220026757
   PubMed Web of Science ®Google Scholar
• GallagherPEFerrarioCMTallantEARegulation of ACE2 in cardiac myocytes and fibroblastsAm J Physiol Heart Circ Physiol2008295H2373H237918849338
   PubMed Web of Science ®Google Scholar
• TallantEAFerrarioCMGallagherPEAngiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptorAm J Physiol Heart Circ Physiol2005289H1560H156615951342
   PubMed Web of Science ®Google Scholar
• AgataJUraNYoshidaHOlmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzymeHypertens Res20062986587417345786
   PubMed Web of Science ®Google Scholar
• SmithRDYokoyamaHAverillDBThe protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristicsAm J Cardiovasc Drugs2006633534217083268
   PubMedGoogle Scholar
• StumpeKOOlmesartan compared with other angiotensin II receptor antagonists: head-to-head trialsClin Ther200426Suppl AA33A3715291378
   PubMedGoogle Scholar
• MiyashitaYSaikiAEndoKEffects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertensionJ Atheroscler Thromb20091662162619907103
   PubMed Web of Science ®Google Scholar
• SmithRDYokoyamaHAverillDBSchiffrinELFerrarioCMReversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptorsJ Am Soc Hypertens2008216517220409899
   PubMed Web of Science ®Google Scholar
• SchiffrinELDengLYLarochellePMorphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patientsClin Invest Med1993161771868365045
   PubMed Web of Science ®Google Scholar
• SchiffrinELDengLYLarochelleP[Prospective study of the effects of an angiotensin converting enzyme inhibitor and a beta blockader on the structure and function of resistant arteries in mild essential hypertension]Arch Mal Coeur Vaiss1994879799817755476
   PubMedGoogle Scholar
• AsmarRRudnichiABlacherJLondonGMSafarMEPulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populationsAm J Hypertens200114919711243313
   PubMed Web of Science ®Google Scholar
• RosensonRSTreatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine productionCardiovasc Drugs Ther20092328929419641984
   PubMed Web of Science ®Google Scholar
• ChrysantSGMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther20083058760418498909
   PubMed Web of Science ®Google Scholar
• ChrysantSGAmlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertensionExpert Rev Cardiovasc Ther2009788789519673666
   PubMedGoogle Scholar
• BarriosVBrommerPHaagUCalderonAEscobarCOlmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig200929427439
   PubMed Web of Science ®Google Scholar
• VolpeMBrommerPHaagUMieleCEfficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig2009291125
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRProspectiveSCAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet20023601903191312493255
   PubMed Web of Science ®Google Scholar
• MouradJJLeJSEffective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig200929419425
   PubMed Web of Science ®Google Scholar
• BasileJNeutelJOvercoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapyTher Adv Cardiovasc Dis2010411912720042448
   PubMedGoogle Scholar
• OparilSChrysantSGKereiakesDResults of an olmesartan medoxomil-based treatment regimen in hypertensive patientsJ Clin Hypertens (Greenwich)20081091192119120717
   PubMed Web of Science ®Google Scholar
• de VinuesaSGGoicoecheaMKanterJInsulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockadeJ Am Soc Nephrol200617S206S21217130263
   PubMed Web of Science ®Google Scholar
• FogariRDerosaGZoppiAEffects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitusHypertens Res200831435018360017
   PubMed Web of Science ®Google Scholar
• FogariRDerosaGZoppiAEffect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patientsIntern Med20084736136618310964
   PubMed Web of Science ®Google Scholar
• KuritaSTakamuraTOtaTOlmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effectsEur J Pharmacol200858831632418501344
   PubMed Web of Science ®Google Scholar
• ZamanAKFujiiSGotoDSalutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesityJ Mol Cell Cardiol20043752553515276022
   PubMed Web of Science ®Google Scholar
• KlagMJWheltonPKRandallBLBlood pressure and end-stage renal disease in menN Engl J Med199633413187494564
   PubMed Web of Science ®Google Scholar
• MiyagawaKDohiYNakazawaARenoprotective effect of calcium channel blockers in combination with an Angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipineClin Exp Hypertens2010321720144066
   PubMed Web of Science ®Google Scholar
• FurukawaTNukadaTMiuraRDifferential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytesJ Cardiovasc Pharmacol20054524124615725949
   PubMed Web of Science ®Google Scholar
• MorikawaTOkumuraMKonishiYOkadaNImanishiMEffects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathyHypertens Res20022557157612358143
   PubMed Web of Science ®Google Scholar
• HallerHVibertiGCMimranAPreventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyJ Hypertens20062440340816508590
   PubMed Web of Science ®Google Scholar
• RitzEVibertiGCRuilopeLMDeterminants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyDiabetologia201053495719876613
   PubMed Web of Science ®Google Scholar
• ChrysantSGMarburyTCSilfaniTNUse of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylateBlood Press Monit20061113514116702822
   PubMed Web of Science ®Google Scholar
• KereiakesDJNeutelJMPunziHAXuJLipkaLJDubielREfficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylateAm J Cardiovasc Drugs2007736137217953475
   PubMed Web of Science ®Google Scholar
• ChrysantSGChrysantGSAntihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazideExpert Opin Pharmacother2004565766715013933
   PubMed Web of Science ®Google Scholar
• ChrysantSGWeberMAWangACHinmanDJEvaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazideAm J Hypertens20041725225915001200
   PubMed Web of Science ®Google Scholar
• IzzoJLJrNeutelJMSilfaniTDubielRWalkerFEfficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration studyJ Clin Hypertens (Greenwich)20079364417215657
   PubMedGoogle Scholar
• QuanAChavanuKMerkelJA review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studiesAm J Cardiovasc Drugs2006610311316555863
   PubMedGoogle Scholar
• RamCVAntihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studiesJ Clin Hypertens (Greenwich)2004656957715470286
   PubMedGoogle Scholar
• VolpeMMieleCHaagUEfficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term studyClin Drug Investig200929381391
   PubMed Web of Science ®Google Scholar
• NeutelJMSmithDHSilfaniTNLeeYWeberMAEffects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertensionJ Hum Hypertens20062025526216397514
   PubMed Web of Science ®Google Scholar
• OgawaHKim-MitsuyamaSJinnouchiTMatsuiKArakawaKRationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (Clinical Trials gov no. NCT00134160)Hypertens Res20093257558019444280
   PubMed Web of Science ®Google Scholar
• OparilSLeeJKarkiSMelinoMSubgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication useJ Cardiovasc Pharmacol20095442743619730391
   PubMed Web of Science ®Google Scholar
• ChrysantSGAmlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combinationDrugs Today (Barc)20084444345318596998
   PubMed Web of Science ®Google Scholar
• ChrysantSGOparilSMelinoMKarkiSLeeJHeyrmanREfficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertensionJ Clin Hypertens (Greenwich)20091147548219751459
   PubMed Web of Science ®Google Scholar
• NeutelJMSmithDHWeberMAWangACMasonsonHNUse of an olmesartan medoxomil-based treatment algorithm for hypertension controlJ Clin Hypertens (Greenwich)2004616817415073470
   PubMedGoogle Scholar
• NeutelJMPrescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patientsCurr Med Res Opin2008242389240118616863
   PubMed Web of Science ®Google Scholar
• OparilSWilliamsDChrysantSGMarburyTCNeutelJComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)2001328329131811588406
   PubMedGoogle Scholar
• OparilSWeberMAngiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapyPostgrad Med2009121253919332960
   PubMed Web of Science ®Google Scholar
• OparilSPimentaEEfficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sexJ Clin Hypertens (Greenwich)20101231320047622
   PubMed Web of Science ®Google Scholar
• CappuccioFPMarkanduNDSagnellaGAEffects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertensionJ Hum Hypertens199151151191830107
   PubMed Web of Science ®Google Scholar
• BramlagePFixed combination of irbesartan and hydrochlorothiazide in the management of hypertensionVasc Health Risk Manag2009521322419436667
   PubMedGoogle Scholar
• BramlagePHasfordJBlood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a reviewCardiovasc Diabetol200981819327149
   PubMed Web of Science ®Google Scholar
• BramlagePFixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertensionExpert Opin Pharmacother2009101755176719538001
   PubMed Web of Science ®Google Scholar
• CalhounDAUse of single-pill combination therapy in the evolving paradigm of hypertension managementExpert Opin Pharmacother2009101869187419496740
   PubMed Web of Science ®Google Scholar
• CalhounDACrikelairNAYenJGlazerRDAmlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safetyAdv Ther2009261012102320024680
   PubMed Web of Science ®Google Scholar
• GuptaAKArshadSPoulterNRCompliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysisHypertension20105539940720026768
   PubMed Web of Science ®Google Scholar
• SicaDARationale for fixed-dose combinations in the treatment of hypertension: the cycle repeatsDrugs20026244346211827559
   PubMed Web of Science ®Google Scholar
• ZarowitzBJFixed-dose combinations for improving medication adherence in assisted living environmentsGeriatr Nurs20072834134518068817
   PubMed Web of Science ®Google Scholar
• MinutoloRGabbaiFBBorrelliSChanging the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trialAm J Kidney Dis20075090891718037091
   PubMed Web of Science ®Google Scholar
• StergiouGSNasothimiouEGDoes dosing antihypertensive drugs at night alter renal or cardiovascular outcome: do we have the evidenceCurr Opin Nephrol Hypertens20081746446918695386
   PubMed Web of Science ®Google Scholar
• BlackHRElliottWJGranditsGPrincipal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialJAMA20032892073208212709465
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGThe Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patientsN Engl J Med200034214515310639539
   PubMed Web of Science ®Google Scholar
• SmithDHDubielRJonesMUse of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartanAm J Cardiovasc Drugs20055415015631537
   PubMedGoogle Scholar